Novel Technology Commercialization

A diagnostic company wanted to assess the current and expected future landscapes for biopharma oncology genomics research and Dx / CDx

A multi-billion dollar life science company needed pre diligence on a potential acquisition target

A leading diagnostics player wanted an assessment of the current and future carrier screening landscape, primarily in the U.S., to guide their product development strategy

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

DeciBio conducted financial projections, valuation, and assisted with messaging to aid client's public listing to NASDAQ

A top-10 diagnostics company wanted to gauge preparedness and reactions to implementation of IVDR, and how that would impact a potential new product